# CMTM5

## Overview
CMTM5 is a gene that encodes the protein CKLF like MARVEL transmembrane domain containing 5, which is a member of the CKLF-like MARVEL transmembrane domain-containing family. This protein is characterized by its four transmembrane domains, which suggest a role in membrane apposition and trafficking. CMTM5 is predominantly expressed in mature oligodendrocytes within the central nervous system (CNS) and plays a critical role in maintaining axonal integrity, although it is not essential for myelin biogenesis. In the peripheral nervous system (PNS), CMTM5 is involved in regulating axonal diameters. The protein's function is influenced by post-translational modifications and exists in different isoforms due to RNA splicing. CMTM5 has been implicated in various diseases, including breast carcinoma and cardiovascular diseases, where its expression levels are associated with disease prognosis and risk factors (Li2010CMTM5v1; Wu2020CMTM57; Zhang2017Validation; Buscham2022Progressive; Buscham2024CMTM5).

## Structure
CMTM5 is a protein characterized by its four transmembrane domains, which are typical of the CKLF-like MARVEL transmembrane domain-containing family. These domains suggest a structural organization that facilitates its role in membrane apposition and trafficking (Li2010CMTM5v1; Buscham2022Progressive). The protein includes small intracellular N-and C-terminal domains and two small extracellular loops, indicating a complex topology that spans the cell membrane (Buscham2022Progressive). Despite its name, CMTM5 does not possess a chemokine-like sequence motif, which implies that its function may not involve direct chemokine signaling (Buscham2022Progressive; Buscham2024CMTM5).

CMTM5 is subject to post-translational modifications, such as phosphorylation, which may influence its function and interactions within the cell. The protein also exists in different isoforms due to RNA splicing, with CMTM5-v1 being a major variant that is secreted via a vesicle-mediated pathway (Li2010CMTM5v1). This secreted form is associated with small vesicles and does not co-localize with typical vesicle markers like CD63, suggesting a unique secretory pathway (Li2010CMTM5v1). The exact tertiary and quaternary structures of CMTM5 remain unspecified in the available literature.

## Function
CMTM5 (CKLF like MARVEL transmembrane domain containing 5) is a protein that plays a crucial role in maintaining axonal integrity within the central nervous system (CNS). It is specifically expressed in mature oligodendrocytes, the cells responsible for forming myelin sheaths around axons, which are essential for proper neural function and signal transmission (Zhan2023Loss; Buscham2024CMTM5). Although CMTM5 is not necessary for myelin biogenesis or structure, its presence is vital for the long-term support of axons. The absence of CMTM5 in oligodendrocytes leads to early-onset and progressive axonal pathology, indicating its importance in preserving axonal health (Buscham2024CMTM5).

CMTM5 is also involved in regulating axonal diameters in the peripheral nervous system (PNS). In Schwann cells, the deletion of CMTM5 results in smaller axonal diameters, suggesting a role in axonal diameter regulation (Buscham2024CMTM5). The protein is predicted to have four transmembrane domains, and while it lacks a chemokine-like sequence motif, its signaling capabilities might be mediated indirectly (Buscham2024CMTM5). The exact molecular mechanisms by which CMTM5 functions remain to be fully elucidated, but it is implicated in pathways that maintain axonal survival, potentially involving NAD+ levels and NMNAT2 (Buscham2024CMTM5).

## Clinical Significance
CMTM5 has been implicated in various diseases due to alterations in its expression levels. In breast carcinoma, CMTM5 is down-regulated compared to normal tissues, and its increased mRNA expression is associated with better relapse-free survival, suggesting a potential tumor-suppressive role (Wu2020CMTM57). This down-regulation is observed across different breast cancer subtypes, including male breast cancer and invasive ductal carcinoma, indicating its broad significance in breast cancer prognosis (Wu2020CMTM57).

In the context of cardiovascular diseases, CMTM5 has been identified as an independent risk factor for cardiovascular events in patients with coronary artery disease. Overexpression of CMTM5 inhibits endothelial cell migration and proliferation, which may contribute to its role in cardiovascular health (Zhang2017Validation). The gene's expression profiles are linked to higher risks of myocardial infarction and mortality, highlighting its potential as a biomarker for cardiovascular risk assessment (Zhang2017Validation).

CMTM5's involvement in these diseases underscores its clinical significance, with potential implications for diagnosis, prognosis, and therapeutic strategies in both cancer and cardiovascular conditions. Further research is needed to fully elucidate its molecular mechanisms and therapeutic potential.


## References


[1. (Li2010CMTM5v1) Henan Li, Xiaohuan Guo, Luning Shao, Markus Plate, Xiaoning Mo, Yu Wang, and Wenling Han. Cmtm5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Reports, 43(3):182–187, March 2010. URL: http://dx.doi.org/10.5483/bmbrep.2010.43.3.182, doi:10.5483/bmbrep.2010.43.3.182. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.5483/bmbrep.2010.43.3.182)

[2. (Wu2020CMTM57) Jun Wu. Cmtm5/7 are biomarkers and prognostic factors in human breast carcinoma. Cancer Biomarkers, 29(1):89–99, September 2020. URL: http://dx.doi.org/10.3233/cbm-191226, doi:10.3233/cbm-191226. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3233/cbm-191226)

[3. (Zhan2023Loss) Jiangshan Zhan, Yuanxu Gao, Leo Heinig, Malena Beecken, Yangbo Huo, Wansong Zhang, Pingzhang Wang, Tianzi Wei, Ruilin Tian, Wenling Han, Albert Cheung Hoi Yu, Markus Kipp, and Hannes Kaddatz. Loss of the novel myelin protein cmtm5 in multiple sclerosis lesions and its involvement in oligodendroglial stress responses. Cells, 12(16):2085, August 2023. URL: http://dx.doi.org/10.3390/cells12162085, doi:10.3390/cells12162085. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12162085)

[4. (Zhang2017Validation) J.W. Zhang, T.F. Liu, X.H. Chen, W.Y. Liang, X.R. Feng, L. Wang, Sidney W. Fu, Timothy A. McCaffrey, and M.L. Liu. Validation of aspirin response-related transcripts in patients with coronary artery disease and preliminary investigation on cmtm5 function. Gene, 624:56–65, August 2017. URL: http://dx.doi.org/10.1016/j.gene.2017.04.041, doi:10.1016/j.gene.2017.04.041. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2017.04.041)

[5. (Buscham2022Progressive) Tobias J Buscham, Maria A Eichel-Vogel, Anna M Steyer, Olaf Jahn, Nicola Strenzke, Rakshit Dardawal, Tor R Memhave, Sophie B Siems, Christina Müller, Martin Meschkat, Ting Sun, Torben Ruhwedel, Wiebke Möbius, Eva-Maria Krämer-Albers, Susann Boretius, Klaus-Armin Nave, and Hauke B Werner. Progressive axonopathy when oligodendrocytes lack the myelin protein cmtm5. eLife, March 2022. URL: http://dx.doi.org/10.7554/elife.75523, doi:10.7554/elife.75523. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.75523)

6. (Buscham2024CMTM5) CMTM5 - a novel CNS myelin protein involved in preserving axonal integrity. This article has 0 citations.